Insider · CIK 0001237419
Werner Cautreels
Files at TRAW (Onconova Therapeutics, Inc.). First filing -, latest -.
In brief
Werner Cautreels files SEC Form 4 as CEO and director at TRAW (Onconova Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Werner Cautreels has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | TRAW Onconova Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +14,150 | $0.00 | $0 | 14,150 | Jul 15, 2026 |
| Mar 8, 2026 | TRAW Onconova Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +31,258 | $0.00 | $0 | 31,258 | Mar 10, 2026 |
| Dec 12, 2025 | TRAW Onconova Therapeutics, Inc. | AGrant or award Common Stock | +4,874 | $0.00 | $0 | 109,222 | Dec 16, 2025 |
| Dec 12, 2025 | TRAW Onconova Therapeutics, Inc. | AGrant or award Stock Option (right to purchase)derivative | +19,496 | $0.00 | $0 | 19,496 | Dec 16, 2025 |
| Oct 12, 2025 | TRAW Onconova Therapeutics, Inc. | AGrant or award Stock Option (right to purchase)derivative | +11,530 | $0.00 | $0 | 11,530 | Oct 15, 2025 |
| Jun 19, 2025 | TRAW Onconova Therapeutics, Inc. | AGrant or award Stock Option (right to purchase)derivative | +23,000 | $0.00 | $0 | 23,000 | Jun 23, 2025 |
| Feb 18, 2025 | TRAW Onconova Therapeutics, Inc. | MOption exercise Common Stock | +96,348 | $0.01 | $963 | 104,348 | Feb 19, 2025 |
| Feb 18, 2025 | TRAW Onconova Therapeutics, Inc. | MOption exercise Pre-Funded Warrant (right to buy)derivative | -96,348 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Dec 29, 2024 | TRAW Onconova Therapeutics, Inc. | POpen-market purchase Pre-Funded Warrant (right to buy)derivative | +96,348 | - | - | 96,348 | Jan 27, 2025 |
| Dec 29, 2024 | TRAW Onconova Therapeutics, Inc. | POpen-market purchase Series A Warrant (right to buy)derivative | +96,348 | - | - | 96,348 | Jan 27, 2025 |
Questions about Werner Cautreels
Answered from the filings on this page, as of the latest one.
Is Werner Cautreels buying or selling?
Werner Cautreels has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Werner Cautreels's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Werner Cautreels has 0.
Where does Werner Cautreels file Form 4?
Werner Cautreels has filed Form 4 at TRAW (Onconova Therapeutics, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.